Skip to content

Advanced endothelial dysfunction in patients with coexistence of coronary artery disease and peripheral arterial disease - effects of Cilostazol on endothelial dysfunction in peripheral arterial disease -

Advanced endothelial dysfunction in patients with coexistence of coronary artery disease and peripheral arterial disease - effects of Cilostazol on endothelial dysfunction in peripheral arterial disease - - Examination concerning the endothelial function of the patients with coexistence of coronary artery disease and peripheral arterial disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000010106
Enrollment
60
Registered
2013-02-25
Start date
2006-08-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The cases with coexistence of coronary artery disease and peripheral arterial disease

Interventions

None listed

Sponsors

Department of Cardiovascular Medicine, Faculty of Sciences, Kumamoto University
Lead Sponsor
Jinnouchi Hospital
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The coronary artery disease (CAD) patient who has a peripheral artery disease (PAD). PAD (1)ABI < 0.9 (2)Fontaine classification >= II (3) previous revascularization in lower limbs (4) occlusive arteries in lower limbs by imaging examinations CAD as the presence of >= 50% narrowing of coronary artery diameter in at least one major coronary artery

Exclusion criteria

Exclusion criteria: (1)heart failure with reduced left ventricular systolic function (ejection fraction<50%) (2)severe valvular heart disease(3)cardiomyopathy (4)systemic illness [including advanced endocrine, hepatic, or renal diseases (5)active inflammatory diseases (6)cancer (7)with residual hemiplegia

Design outcomes

Primary

MeasureTime frame
endothelial evaluation of function by reactive hyperemia peripheral arterial tonometry

Secondary

MeasureTime frame
The effect of Cilostazol to the peripheral artery disease patients

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026